Targeted Therapy Improves Long-Term Outcomes for Patients with Rare Mutations Driving Lung Cancer
Mass General Brigham Cancer Institute study found that patients with advanced RET fusion-positive lung cancer showed robust and durable responses.
Press Release5 Minute ReadApr | 4 | 2022
Saumya Das, MD, PhDThe past decade has seen investigators discover new functions of RNAs that do not translate into proteins.
BOSTON – The body’s ability to respond to various types of stress is essential for maintaining health, and failure of such adaptive stress responses can trigger or worsen numerous diseases. New research led by investigators at Massachusetts General Hospital (MGH) and published in Advanced Science reveals that cells often release certain RNA molecules called tDRs in response to stressors, and that different tDRs may serve as markers of cellular stress in different diseases.
“RNA molecules have long been known to be the messenger between DNA (the genetic code) and proteins (the functional molecules of the cell); however, the past decade has seen investigators discover new functions of RNAs that do not translate into proteins—the so-called non-coding RNAs,” says senior author Saumya Das, MD, PhD, co-director of the Resynchronization and Advanced Cardiac Therapeutics Program at MGH.
Das notes that there’s a growing list of non-coding RNAs with diverse functions, and among these, a new class of RNAs has been found to arise from so-called transfer RNAs that normally function to help make proteins from classic messenger RNAs. These RNAs, called tRNA-derived small RNAs (tDRs), appear to be generated when larger “parent” tRNAs are cut into smaller versions by stress-activated enzymes.
By studying a variety of human and rat cells under three stressors—nutritional deprivation, low oxygen and oxidative stress—that are often present in many disease states, Das and his colleagues generated a comprehensive landscape of tDRs that can be found inside cells (cellular) and outside cells (extracellular) during different stress responses. They also found that key proteins called RNAses are important for the generation and stability of extracellular tDRs.
“While tDRs play important roles in cellular functions, we have also found that tDRs are released by cells where they may serve as markers of cellular stress in different diseases,” says lead author Guoping Li, PhD, an instructor in medicine at MGH and Harvard Medical School. “We saw that different types of stress signals can affect the cellular and extracellular tDRs in different types of cells, and that there are ‘signatures’ of these stress signals.”
The team created an atlas of the stress signatures for both cellular and extracellular tDRs that can be used not only as indicators of disease but also as a starting point for scientists who are interested in studying the roles of distinct tDRs in cancer, fibrosis, and other conditions. Das and colleagues are focusing on one such tDR and its role in kidney disease.
The study’s co-authors include Guoping Li, Aidan C. Manning, Alex Bagi, Xinyu Yang, Priyanka Gokulnath, Michail Spanos, Jonathan Howard, Patricia P. Chan, Thadryan Sweeney, Robert Kitchen, Haobo Li, Brice D. Laurent, Sary F. Aranki, Maria I. Kontaridis, Louise C. Laurent, Kendall Van Keuren-Jensen, Jochen Muehlschlegel, and Todd. M. Lowe.
This work was supported by the American Heart Association and the National Institutes of Health.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals." MGH is a founding member of the Mass General Brigham health care system.
Mass General Brigham Cancer Institute study found that patients with advanced RET fusion-positive lung cancer showed robust and durable responses.
Mass General Brigham researchers used artificial intelligence to analyze routine medical scans, uncovering how the thymus impacts aging, cardiovascular risk, cancer incidence, and response to immunotherapy.
Mass General Brigham has received a $50 million gift that will shape the future of cancer care and discovery by empowering the next generation of gene and cell therapy research.
The Sean M. Healey & AMG Center for ALS at Mass General Brigham has contracted with Keros Therapeutics, Inc. (Keros) to design a new Healey ALS MyMatch trial evaluating rinvatercept (KER-065).
The Sean M. Healey & AMG Center for ALS at Mass General Brigham is pleased to announce that the first participant received study medication in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 by Neurizon Therapeutics.
Investigators from Mass General Brigham analyzed data from nearly 4,300 stable outpatients with chest pain and no known prior CAD and found that, although women had smaller plaque volumes and fewer plaques with high-risk characteristics, they experienced similar rates of MACE compared with men.